I doubt we can call it up ramping...I was first sceptical on BOT...

I doubt we can call it up ramping...

I was first sceptical on BOT few years back but saw huge potential...

since those early days, our pipeline grew only stronger..

1. Japan has proven sales and growth 48% YoY - fact
2. Market share in Japan after 2 years over 3% for sure..I remember it being approx 5%
3. US population 3x bigger and insurance companies will reimburse - fact
4 . Drug is novel and much better then anything on the market...and easy to use and buy..- fact
5. Company said on Webinar that over 50% dermatologists will aim to prescribe it..- fact
6. Financial mathematics at 1% of market share should give us SP approx usd 1 - fact
7. World class derma team - fact

The rest is your imagination, lost opportunity -

see you in 2-3 weeks , but FDA will give it to us this time....and we are ready to SELL...